Biontech presents positive phase 1/2 data update for car-t cell therapy candidate bnt211 in advanced solid tumors at esmo congress 2023

Mainz, germany, october 23, 2023 (globe newswire) –  biontech se (nasdaq: bntx, “biontech” or “the company”) today announced follow-up data from its ongoing first-in-human phase 1/2 trial (nct04503278; 2019-004323-20) evaluating the safety and efficacy of the company's claudin-6 (cldn6)-directed car-t cell therapy candidate bnt211 in patients with cldn6-positive refractory/relapsed solid tumors. the data show encouraging signs of clinical activity and an increased persistence of cancer-specific car-t cells when combined with carvac. at the esmo congress 2023 in madrid, prof. john haanen, m.d., ph.d., netherlands cancer institute (nki), amsterdam, netherlands presented the data in an oral late-breaking data session which confirms the positive interim data presented at this year's american society of clinical oncology (asco) annual meeting in chicago, usa.
BNTX Ratings Summary
BNTX Quant Ranking